Phytoplant Research S.L. Becomes First Spanish Company to Earn GLOBALG.A.P. Certification for the Cultivation of Cannabis as raw material for purification / extraction of active ingredients

CORDOBA, Spain, Nov. 6, 2017 /PRNewswire/ -- Life sciences firm Phytoplant Research S.L. has received certification from GLOBALG.A.P. in recognition of its commitment to best practices in medicinal Cannabis production.

The certificate was issued on July 17, 2017, and will be valid for one year. With this announcement, Phytoplant Research becomes one of the only projects of its kind in Europe to have earned GLOBALG.A.P. certification.

Dr. Salvatore Casano, manager of the department of breeding and cultivation at Phytoplant Research, stated this about the GLOBALG.A.P. certification: "We have been working for over 5 years now to breed new varieties of medicinal Cannabis that adapt to the growing conditions of south of Spain, using natural sunlight. We are proud to have achieved this important objective — receiving the GLOBALG.A.P. certificate not only validates the quality of our industrial production chain but also recognizes the legitimacy of our plant varieties registered in the European Community Plant Variety Office (CPVO)."

Phytoplant Research's work with raw Cannabis material includes cultivation, harvesting, drying, processing, and packaging. For the past several years, the firm has worked to develop a viable production model for the western Andalusia region. This model consists of high tunnels and associated structures that allow for all necessary raw material production phases. The resulting medicinally valuable compounds include Cannabidiol (CBD), Cannabigerol (CBG) and Cannabigerol acid (CBGA).

In the context of Cannabis production, GLOBALG.A.P. certification entails a set of standards covering the entire production process — from the delivery of nursery plants to the harvesting and handling of dry raw material from the mature plants. The most recent update to the certification (version 5.0) added several new standards, including the requirement that producers work only with officially registered plant varieties, and to fully respect relevant intellectual property laws. At Phytoplant Research, GLOBALG.A.P. certification addresses the following CPVO varieties: Sara (2015/0098), Pilar (2016/0115), Theresa (2016/0116), Juani (2016/0117), Aida (2016/0167) and Octavia (2017/0148). Additionally, all plant varieties are propagated asexually by Phytoplant Research to increase standardization. More info about Phytoplant's CBG varieties can be found here.

GLOBALG.A.P. is an international organization committed to facilitate "Good Agricultural Practice." Its primary goal is to incentivize safe, sustainable agriculture through certifications and benchmarks, as well as a complex system that harmonizes GLOBALG.A.P.'s many certifications. Members share the organization's vision and work to influence their local agricultural networks and effect positive moves toward sustainability, safety and quality.

Looking ahead, Phytoplant Research plans to continue developing new varieties of Cannabis and engineering new methods of extraction and purification of cannabinoids.

About Phytoplant Research

Phytoplant Research S.L. is a privately-owned Spanish company founded in 2008 and active in the field of phytotherapy research. The company specializes in developing the industrial chain of medicinal plants, from selection and breeding to registration (for example, at CPVO), cultivation of registered varieties and obtaining derived products.

Phytoplant Research S.L. focuses on research and development products that contain plant material and extracts, as well as essential and seed oils. These products represent significant economic potential for the pharmaceutical, nutraceutical and dermocosmetic industries. The company also wants to ensure the industrial supply of phyto-pharmaceutical quality raw materials through the cultivation of medicinal plants and extraction of plant material, with the objective of isolating, purifying and manufacturing naturally active ingredients (psychotropic and non-psychotropic), semi-synthetic, biotransformed, pharmaceutically acceptable salts and derivatives.

Phytoplant Research S.L. is committed to the quality, safety and innovation of the full range of its products and services.

If you are interested to read more about the latest R&D of Phytoplant Research S.L. please visit:
http://www.phytoplant.es/news

Contact:

Stefan Martin Meyer, CEO Phytoplant Research S.L.  
Tel: +34 957 10 16 29  
Email: media@phytoplant.es